Urogen Pharma Ltd
(URGN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -105,146 | -75,657 | -20,000 | -1,941 | -12,689 |
| Depreciation Amortization | -276 | 417 | 207 | 213 | 113 |
| Accounts receivable | N/A | N/A | 83 | -83 | N/A |
| Other Working Capital | 3,410 | 7,164 | 3,757 | 1,210 | 609 |
| Other Operating Activity | 30,995 | 30,742 | 6,385 | 4,790 | 4,792 |
| Operating Cash Flow | $-71,017 | $-37,334 | $-9,568 | $4,189 | $-7,175 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -145,096 | 35,901 | -36,001 | N/A | N/A |
| PPE Investments | -325 | -560 | -271 | -695 | -301 |
| Other Investing Activity | -172 | -54 | -5 | -98 | 0 |
| Investing Cash Flow | $-145,593 | $35,287 | $-36,277 | $-793 | $-301 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 165,326 | 66,636 | 61,245 | N/A | N/A |
| Other Financing Activity | -76 | -215 | 340 | -9 | 21,581 |
| Financing Cash Flow | $165,250 | $66,421 | $61,585 | $-9 | $21,581 |
| Beginning Cash Position | 101,571 | 37,197 | 21,457 | 17,975 | 3,870 |
| End Cash Position | 50,211 | 101,571 | 37,197 | 21,362 | 17,975 |
| Net Cash Flow | $-51,360 | $64,374 | $15,740 | $3,387 | $14,105 |
| Free Cash Flow | |||||
| Operating Cash Flow | -71,017 | -37,334 | -9,568 | 4,189 | -7,175 |
| Capital Expenditure | -325 | -560 | -271 | -695 | -301 |
| Free Cash Flow | -71,342 | -37,894 | -9,839 | 3,494 | -7,476 |